Objective: Psychiatric inpatients represent an acutely vulnerable population with high rates of suicidality (ie, suicidal ideation, attempts, and completed suicide). This systematic review aimed to evaluate treatments for suicidality delivered within inpatient settings. Data Sources: MEDLINE, Embase, APA PsycInfo, CINAHL, and The Cochrane Library were systematically searched using 3 concepts:...
Airway management and endotracheal intubation are essential skills of emergency medicine. Patients with acute brain injury or ischemia have complex physiology, and without caution, endotracheal intubation can inadvertently lead to secondary brain injury. This article summarizes the evidence behind airway management for patients with acute brain injury or ischemia. We present data that will help...
ABSTRACT There is growing interest to investigate classic psychedelics as potential therapeutics for mental illnesses. Previous studies have demonstrated that one dose of psilocybin leads to persisting neural and behavioral changes. The durability of psilocybin’s effects suggests that there are likely alterations of gene expression at the transcriptional level. In this study, we performed...
Major depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emerging pharmacologic treatments for MDD, focusing on their mechanisms of action, clinical...
N-methyl-D-aspartate receptor (NMDAR) antagonists, including ketamine, phencyclidine (PCP), and dizocilpine (MK-801), are an important class of drugs that can produce antidepressant, hallucinogenic, dissociative, psychotomimetic, and anesthetic effects in humans and animal models. To understand the effects of NMDAR antagonists on the brain, it is essential to map their actions at cellular...
Introduction: Depression is a multifaceted disorder with a limited therapeutic repertoire. A significant breakthrough in depression research has been the discovery of fast-acting antidepressants that target the glutamate/GABA system, namely ketamine and neurosteroids. Positive modulation of GABA A receptors containing the a5 subunit (a5GABAARs) represents a promising new approach for targeted...
NeuroImage: Clinical2025Gianna M. Perez, Benjamin M. Rosenberg, Wenyi Xu et al.3 citations
BACKGROUND: Understanding changes in brain activity following treatment is critical to advancing the use of neuroimaging in psychiatric research. Previous work has focused on defining abnormalities (biomarkers) between patients and healthy controls but there has been less investigation of brain changes in depression patients following treatment. To boost sample size and explore the possibility...
Mental health disorders such as depression are a rising issue among university students. Some of them use complementary and alternative medicine (CAM) as self-administered therapy instead of or together with professional care. Defining the scale of the problem, its underlying reasons and possible implications are crucial for addressing it in clinical psychiatry and public health strategies. A...
Depressive disorders continue to pose a major clinical challenge worldwide, particularly given the high prevalence and increasing number of treatment-resistant cases. Over the past decade, advances in research have elucidated the antidepressant potential of psilocybin and other 5-HT₂A receptor agonists in patients with major depressive disorder (MDD) and treatment-resistant depression (TRD)....
With the use of ketamine, Glutamate (Glu) system has gradually become the focus of antidepressant effects. N-methyl-D-aspartate receptor (NMDAR), as one of the major ionic glutamate receptors, plays a dominant role in antidepressant effects, especially in synaptic plasticity. Few studies have been conducted on changes of NMDAR-related indicators and inflammatory cytokines in major depressive...